Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)
June 07 2022 - 8:41AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
________________
FORM 6-K
________________
REPORT OF FOREIGN PRIVATE ISSUER
Pursuant to Rule 13a-16 or 15d-16
of the Securities Exchange Act of 1934
June 7, 2022
________________
NOVO NORDISK A/S
(Exact name
of Registrant as specified in its charter)
Novo Allé
DK- 2880, Bagsvaerd
Denmark
(Address of principal executive offices)
________________
Indicate by check mark whether the registrant files or will file annual reports under
cover of Form 20-F or Form 40-F
| Form 20-F [X] |
Form 40-F [ ] |
Indicate by check mark whether the registrant by furnishing the information contained
in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange
Act of 1934.
If “Yes” is marked, indicate below the file number assigned to the registrant
in connection with Rule 12g-32(b):82-________
Novo
Nordisk – major shareholder announcement
Bagsværd,
Denmark, 7 June 2022 – Novo Nordisk today announced that the company has been notified by BlackRock, Inc. (Blackrock)
that Blackrock as of 31 May 2022 holds B shares equal to below 5% of the entire share capital of Novo Nordisk. The announcement is in
accordance with section 30 of the Danish Capital Markets Act.
The total B shares according to section 38 of the Danish Capital
Markets Act, and other financial instruments according to section 39(2)(1) of the Danish Capital Markets Act and financial instruments
with similar effects according to section 39(2)(2) of the Danish Capital Markets Act held by Blackrock correspond to below 5% of the
entire share capital and below 5% of the voting rights.
For a full chain of controlled undertakings through which
the voting rights and/or the financial instruments are held, please see the annex.
About Novo Nordisk
Novo Nordisk is a leading global healthcare company, founded in
1923 and headquartered in Denmark. Our purpose is to drive change to defeat diabetes and other serious chronic diseases such as obesity
and rare blood and endocrine disorders. We do so by pioneering scientific breakthroughs, expanding access to our medicines and working
to prevent and ultimately cure disease. Novo Nordisk employs about 49,300 people in 80 countries and markets its products in around 170
countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO).
or more information, visit novonordisk.com, Facebook, Twitter, LinkedIn and YouTube.
Page 2 of 3
Further information
| Media: |
|
|
| Ambre Brown Morley |
+45 3079 9289 |
abmo@novonordisk.com |
| Natalia Salomao Abrahao |
+1 848 304 1027 |
niaa@novonordisk.com |
| |
|
|
| Investors: |
|
|
| Daniel Muusmann Bohsen |
+45 3075 2175 |
dabo@novonordisk.com |
| Ann Søndermølle Rendbæk |
+45 3075 2253 |
arnd@novonordisk.com |
| David Heiberg Landsted |
+45 3077 6915 |
dhel@novonordisk.com |
| Jacob Martin Wiborg Rode |
+45 3075 5956 |
jrde@novonordisk.com |
| Mark Joseph Root (US) |
+1 848 213 3219 |
mjhr@novonordisk.com |
Page 3 of 3
Annex: Full chain of controlled undertakings starting with
the ultimate controlling natural person or legal entity as of 31 May 2022
| Name |
% of voting rights if it equals or is higher than the notifiable threshold |
% of voting rights through financial instruments if it equals or is higher than the notifiable threshold |
Total of both if it equals or is higher than the notifiable
threshold |
| BlackRock Japan Co., Ltd. |
|
|
Below 5% |
|
BlackRock Investment
Management, LLC |
|
|
Below 5% |
|
BlackRock Investment
Management (UK) Limited |
|
|
Below 5% |
|
BlackRock Investment Management (Australia)
Limited |
|
|
Below 5% |
|
BlackRock International
Limited |
|
|
Below 5% |
|
BlackRock Institutional Trust Company, National
Association |
|
|
Below 5% |
| BlackRock Fund Advisors |
|
|
Below 5% |
|
BlackRock Financial
Management, Inc. |
|
|
Below 5% |
|
BlackRock Asset Management North Asia
Limited |
|
|
Below 5% |
|
BlackRock Asset Management Deutschland
AG |
|
|
Below 5% |
|
BlackRock Asset Management Canada
Limited |
|
|
Below 5% |
| BlackRock Advisors, LLC |
|
|
Below 5% |
|
BlackRock Advisors (UK)
Limited |
|
|
Below 5% |
|
BlackRock (Singapore)
Limited |
|
|
Below 5% |
|
BlackRock Asset Management Ireland
Limited |
|
|
Below 5% |
Novo Nordisk A/S
Investor Relations |
Novo Allé
2880 Bagsværd
Denmark |
Telephone:
+45 4444 8888 |
Internet:
www.novonordisk.com
CVR no:
24 25 67 90 |
| |
|
Company announcement No 50 / 2022 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has
duly caused this report to be signed on its behalf of the undersigned, thereunto duly authorized.
| Date: June 7, 2022 |
NOVO NORDISK A/S
Lars Fruergaard Jørgensen
Chief Executive Officer |
Novo Nordisk (PK) (USOTC:NONOF)
Historical Stock Chart
From Oct 2024 to Nov 2024
Novo Nordisk (PK) (USOTC:NONOF)
Historical Stock Chart
From Nov 2023 to Nov 2024
